共 40 条
[31]
MODIFIED DISEASE-ACTIVITY SCORES THAT INCLUDE 28-JOINT COUNTS - DEVELOPMENT AND VALIDATION IN A PROSPECTIVE LONGITUDINAL-STUDY OF PATIENTS WITH RHEUMATOID-ARTHRITIS
[J].
ARTHRITIS AND RHEUMATISM,
1995, 38 (01)
:44-48
[36]
Sinigaglia L, 2000, J RHEUMATOL, V27, P2582
[38]
Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial
[J].
ANNALS OF THE RHEUMATIC DISEASES,
2019, 78 (07)
:899-907
[39]
Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
[J].
ANNALS OF THE RHEUMATIC DISEASES,
2016, 75 (06)
:983-990
[40]
Terpos E, 2011, CLIN EXP RHEUMATOL, V29, P921